Trial Profile
URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra-223 Dichloride Treated mCRPC Patients in a Real Life Setting in Germany.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms URANIS
- Sponsors Bayer
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.
- 24 Aug 2020 Planned End Date changed from 26 Aug 2020 to 17 Sep 2020.
- 29 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 3 Aug 2020.